Alliance Pharma has taken a £79.3m ($101m) non-cash impairment charge, more than half of which relates to US menopause dietary supplement brand Amberen.
Filing its 2023 annual report – the publication of which was setback by an audit delay – the UK-based firm said the impairment was due to lowered future cash flow expectations and higher cost of capital, of which £46.4m related to Amberen, £10
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?